New hope for Alzheimer's? phase 3 trial of brain-fueling compound begins
NCT ID NCT05809908
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether a daily dose of tricaprilin, a type of fat that may provide energy to brain cells, can improve memory, thinking, and daily function in people with mild-to-moderate Alzheimer's disease. About 535 participants will receive either tricaprilin or a placebo for 26 weeks. The goal is to see if this approach can slow down cognitive decline.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of dementia cases reshape how we care for patients?
- PET scans probe link between brain inflammation and Alzheimer's damage
- Can sound waves soothe Dementia's emotional turmoil?
- Can a Low-Dose immune calmer slow Alzheimer's decline?
- A stumble before memory slips? study tests if falls predict Alzheimer's
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?